Company: ACBM
Filing Date: 2025-07-23
Form Type: 10-Q
Source: 0001640334-25-001279
Chunk: 4

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-23
Form: 10-Q
Item: Item 2
Chunk 4
---
 June 30, 2024, we had no revenue or cost of revenue.  Our operating expenses were $9,086 which are primarily relating to expenses and professional fees relating to our status as a public company. We also incurred interest expense to a minority stockholder of $1,057. As a result, we had a net loss of $10,143 or $(0.00) per share (basic and diluted).

For the three months ended June 30, 2023, we had no revenue or cost of revenue.  Our operating expenses were $3,194,700, of which $1,878,275 represented research and development expenses related primarily to the development of cordyceps-infused chicken feed, and $1,316,425 represented selling, general and administrative expenses, of which $1,245,175 related to services provided by our consultants and $71,250 to expenses and professional fees relating to our status as a public company. The compensation to our consultants for research and development services and selling, general and administrative services totaling $3,123,450 represented the amortization of deferred stock compensation issued to the consultants in 2021. We also incurred interest expense to a minority stockholder of $789. As a result, we had a net loss of $3,195,489 or $(0.05) per share (basic and diluted).

For the six months ended June 30, 2024, we had no revenue or cost of revenue.  Our operating expenses were $19,384 which are primarily relating to expenses and professional fees relating to our status as a public company. We also incurred interest expense to a minority stockholder of $2,011. As a result, we had a net loss of $21,395 or $(0.00) per share (basic and diluted).

For the six months ended June 30, 2023, we had no revenues or cost of revenues, and we incurred operating expenses of $7,198,266, of which $4,398,275 represented research and development expenses related primarily to the development of cordyceps-infused chicken feed, $2,799,991 represented selling, general and administrative expenses, of which $2,653,275 related to services provided by our consultants and $146,716 to expenses and professional fees relating to our status as a public company. The compensation to our consultants for research and development services and selling, general and administrative services totaling $7,051,550 represented the amort